Get the Stockscreener App
1.64
2.50%
0.04
After Hours:
1.64
Telomir Pharmaceuticals Inc stock is traded at $1.64, with a volume of 2.20M.
It is up +2.50% in the last 24 hours and up +20.59% over the past month.
Telomir Pharmaceuticals Inc is a pioneering preclinical-stage pharmaceutical company which leads the advancement of age-reversal science. The Company is focused on developing Telomir-1, a novel small molecule designed to lengthen and protect telomeres-the protective DNA end caps of chromosomes that are crucial to cellular aging. As humans and animals age, telomeres naturally shorten, with metal reactivity accelerating this process, increasing the risk of degenerative and age-related diseases. By addressing the underlying causes of aging at the cellular level, Telomir aims to tackle the root of these conditions rather than simply treating their symptoms. Telomir is conducting ongoing preclinical research into Progeria, diabetes, cancer, Alzheimer's disease, osteoarthritis, and others.
See More
Previous Close:
$1.60
Open:
$1.745
24h Volume:
2.20M
Relative Volume:
0.45
Market Cap:
$52.94M
Revenue:
-
Net Income/Loss:
$-16.14M
P/E Ratio:
-3.037
EPS:
-0.54
Net Cash Flow:
$-3.99M
1W Performance:
-8.89%
1M Performance:
+20.59%
6M Performance:
-40.15%
1Y Performance:
-65.18%
1-Day Range:
$1.63
$1.75
1-Week Range:
$1.53
$2.091
52-Week Range:
$1.12
$7.0791
Telomir Pharmaceuticals Inc Stock (TELO) Company Profile
Name
Telomir Pharmaceuticals Inc
Sector
Industry
Phone
786-396-6723
Address
100 SE 2ND ST, MIAMI
Compare TELO with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
TELO
Telomir Pharmaceuticals Inc
|
1.64 | 54.13M | 0 | -16.14M | -3.99M | -0.54 |
|
VRTX
Vertex Pharmaceuticals Inc
|
412.22 | 104.45B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
469.36 | 60.95B | 2.46B | -319.09M | -52.09M | -2.4669 |
|
REGN
Regeneron Pharmaceuticals Inc
|
572.60 | 59.11B | 14.21B | 4.46B | 3.56B | 39.69 |
|
ARGX
Argen X Se Adr
|
812.95 | 49.23B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ONC
Beone Medicines Ltd Adr
|
320.94 | 35.92B | 4.56B | -176.77M | 225.30M | -1.7177 |
Telomir Pharmaceuticals Inc Stock (TELO) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Feb-21-25 | Initiated | Rodman & Renshaw | Buy |
Telomir Pharmaceuticals Inc Stock (TELO) Latest News
Telomir Pharmaceuticals Announces New Data Showing That Telomir-1 Kills Aggressive Pancreatic Cancer Cells, One of the Deadliest Forms of Cancer - Beaver County Times
What to do if you’re stuck in Telomir Pharmaceuticals Inc.2025 Volatility Report & Weekly High Momentum Picks - newser.com
Telomir-1 shows efficacy against pancreatic cancer cells in lab study - Investing.com UK
Telomir Pharmaceuticals reports new preclinical data on pancreatic cancer By Investing.com - Investing.com UK
Telomir Pharmaceuticals Unveils Promising Pancreatic Cancer Findings - TipRanks
Telomir Pharmaceuticals reports new preclinical data on pancreatic cancer - Investing.com
Telomir Pharmaceuticals Announces New Data on Telomir-1's Impact on Pancreatic Cancer - TradingView
Custom watchlist performance reports with Telomir Pharmaceuticals Inc.Market Activity Summary & Safe Investment Capital Preservation Plans - newser.com
Telomir Pharmaceuticals Inc. stock outlook for YEARDip Buying & Fast Momentum Stock Entry Tips - newser.com
Does Telomir Pharmaceuticals Inc. show high probability of reboundEarnings Beat & Free Community Consensus Stock Picks - newser.com
Tools to assess Telomir Pharmaceuticals Inc.’s risk profileWeekly Investment Report & Fast Moving Trade Plans - newser.com
Why Telomir Pharmaceuticals Inc. is moving todayMarket Rally & Free Community Supported Trade Ideas - newser.com
Telomir Pharmaceuticals Inc Stock Analysis and ForecastLong-Term Investment Plans & Download Our Free Trading Blueprint - earlytimes.in
What drives Telomir Pharmaceuticals Inc stock priceIndustrial Stocks Review & Free Transform Portfolio With Stocks - earlytimes.in
Telomir Pharmaceuticals Announces New Findings in a Prostate Cancer Model Demonstrating Telomir-1 Also Resets DNA Methylation of Tumor Suppressor Genes Implicated in Two of the Most Persistent Challenges in Oncology-Metastasis and Treatment Re - Shreveport Times
Why Telomir Pharmaceuticals Stock Is Rising 40% Premarket Today - Stocktwits
Telomir Pharmaceuticals Reports Discovery That Telomir-1 Selectively Kills Aggressive Triple-Negative Breast Cancer Cells - DelmarvaNow.com
Institutional scanner results for Telomir Pharmaceuticals Inc.2025 Fundamental Recap & Risk Controlled Stock Alerts - newser.com
How to monitor Telomir Pharmaceuticals Inc. with trend dashboardsJuly 2025 Trade Ideas & Daily Chart Pattern Signal Reports - newser.com
Telomir Pharmaceuticals Inc. (TELO) Stock Price | Live Quotes & Charts | NSC - StocksToTrade
Why Is Telomir Pharmaceuticals Stock Trading Higher Today?Telomir Pharmaceuticals (NASDAQ:TELO) - Benzinga
Telomir Pharmaceuticals Announces In Vitro Data Showing Telomir-1 Targets Additional Histone Demethylase Families, a Unique Profile in Cancer and Aging Not Seen in Other Therapies - The Florida Times-Union
Telomir stock soars after drug shows promise against aggressive breast cancer - Investing.com
Telomir Pharma’s Cutting-Edge Cancer Breakthrough - StocksToTrade
Telomir’s Investigational Therapy: A Game Changer? - timothysykes.com
Pre-Market Titans: TTRX, BJDX & UPC Set The Pace - RTTNews
Telomir-1 shows promise against triple-negative breast cancer By Investing.com - Investing.com South Africa
Selective killing of aggressive TNBC cells: Telomir's Telomir‑1 disrupts iron-driven energy and mitochondrial function - Stock Titan
Why Richardson Electronics Shares Are Trading Higher By Over 20%; Here Are 20 Stocks Moving Premarket - inkl
Telomir Pharmaceuticals Inc Stock (TELO) Financials Data
Revenue
Net Income
Cash Flow
EPS
5.15%
1.45%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):